|
Notice of Funding Opportunities (NOFOs): Cancer Prevention Clinical Trials and More |
|
Cancer Prevention Clinical Trials Network (CP-CTNet)
Through these NOFOs, NCI proposes and will support the Cancer Prevention Clinical Trials Network (CP-CTNet) sites and the CP-CTNet Data Management, Auditing, and Statistical Center (DMASC). CP-CTNet sites across the United States perform early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions.
RFA-CA-24-024: CP-CTNet Sites (UG1 Clinical Trial Required)
RFA-CA-24-025: CP-CTNet: DMASC (UG1 Clinical Trial Required)
Important Dates and Deadlines
- Letters of Intent due: August 23, 2024
- Pre-Application Webinars: August 27, 2024
- Applications due: October 31, 2024
- Expires: November 1, 2024
For more information on these NOFOs, contact Eva Szabo, M.D.
CP-CTNet Pre-Application Webinars
Pre-application webinars will be held for prospective applicants to provide an overview of the two NOFOs for the CP-CTNet:
CP-CTNet Sites (RFA-CA-24-024)
Tuesday, August 27
1:00-2:00 p.m. ET
Register in advance
CP-CTNet: DMASC (RFA-CA-24-025)
Tuesday, August 27
2:30-3:30 p.m. ET
Register in advance
Questions after the webinars can be sent to CP-CTNet@mail.nih.gov.
|
Request for Information (RFI): Opportunities and Challenges in Enabling and Advancing Precision Medicine Artificial Intelligence (AI) by Integrating Clinical Imaging with Multimodal Data
The National Institutes of Health (NIH) invites public comments on the current challenges and opportunities in enabling precision medicine with AI by integrating medical images with other data types to support clinical decision making.
Learn more and submit your ideas on the NIH Common Fund submission website: https://commonfund.nih.gov/ai-rfi.
NOT-RM-24-011
Responses due: September 23, 2024, by 5:00 p.m. ET
Notice of Special Interest (NOSI): Advancing Diet and Physical Activity Biomarkers for Assessing Lifestyle Interventions in Cancer Prevention and Cancer Interception Research
This NOSI encourages applications focused on improving diet and/or physical activity assessment biomarker development for evaluating lifestyle-based cancer prevention and interception approaches across diverse settings. This NOSI replaces NOT-CA-24-060, published June 12, 2024.
NOT-CA-24-074
Expires: January 8, 2027
|
|
|
FDA Approves HPV Tests That Allow for Self-Collection in a Health Care Setting
On May 14, the Food and Drug Administration (FDA) expanded the approvals of two tests that detect cancer-causing types of human papillomavirus (HPV) in the cervix. Both tests are used as part of screening for cervical cancer.
In this NCI Cancer Currents Blog, DCP's Dr. Vikrant Sahasrabuddhe explains how the FDA's recent expanded approvals of self-collection devices for HPV screening relates to the recently launched SHIP (Self-collection for HPV testing to Improve Cervical Cancer Prevention) Trial.
Read the NCI Cancer Currents Blog.
|
ULACNet Update - August 2024
Highlights from the latest edition of ULACNet Update, a newsletter with programmatic and research updates from the US-Latin American-Caribbean HIV/HPV-Cancer Prevention Clinical Trials Network (ULACNet), include:
- Living with HIV and Preventing Cervical Cancer: Launch of a Transformative Study – ULACNet 202
- Accrual Quality Improvement Program (AQuIP) Analysis: Assessing Patient Enrollment in ULACNet Screening Studies
- Screening for and Prevention of Anal Cancer as Standard of Care for People with HIV: The New Guidelines
- Auditing The ULACNet Program: One Aspect of Quality Assurance
Read more in ULACNet Update.
|
|
|
Impact of Diet on Mucosal Immunity and Immune-mediated Digestive Diseases
 Wednesday, August 21-Thursday, August 22 (Hybrid Meeting)
Advance registration required (Aug 14 deadline for in-person attendees only) Location: NIAID Conference Center, Rockville, MD, or Zoom
This trans-NIH workshop will focus on understanding the critical dietary factors that regulate the gastrointestinal immune system. Presentations will explore the impact of dietary exposures on the gut microbiome, and the impact of diet on immune-mediated digestive diseases, such as inflammatory bowel disease, cancer, and food allergies.
Learn more about this workshop and view the agenda.
NCI Small Business Innovative Research (SBIR) Fiscal Year 2025 Contract Solicitation Webinar
Thursday, August 22
2:00-3:30 p.m. ET
Advance registration required
Consider attending this webinar to learn more about NCI SBIR contract solicitation topics, including development of cancer immunoprevention agents (NIH/NCI 467) and precision nutrition interventions to reduce cancer-related symptoms (NIH/NCI 470). The full list of contract solicitation topics is available at: https://sbir.cancer.gov/small-business-funding/contracts/current-solicitation.
Proposals are due by Friday, October 18 at 5:00 p.m. ET.
Building Bridges in Cancer Symptom Science: Interventions for Cancer-related Cognitive Impairment (CRCI)
Monday, August 26
3:00-4:00 p.m. ET
Advance registration required
In this webinar, Agnès Lacreuse, Ph.D., from University of Massachusetts Amherst, will discuss pharmacological interventions for cognitive decline induced by aromatase-inhibitor therapy in a marmoset model. Diane Von Ah, Ph.D., R.N., FAAN, from Ohio State University’s College of Nursing and Comprehensive Cancer Center, will then discuss cognitive training interventions for cancer-related cognitive impairment.
Learn more about the Building Bridges in Cancer Symptom Science Webinar Series.
|
Microbial Host Defense and Effect on Cancer Initiation and Progression
Wednesday, September 11
1:00–2:00 p.m. ET
Advance registration required
Florencia McAllister, M.D., associate professor at the University of Texas MD Anderson Cancer Center, will give a talk on microbial host defense and effect on cancer initiation and progression as part of the NCI DCP Immunology Interest Group Seminar Series.
Learn more about the seminar.
|
|
|
|
|
|
